OBJECTIVE: To compare the antihypertensive efficacy of olmesartan medoxomil with that of candesartan cilexetil after 1, 2 and 8 weeks of treatment. DESIGN AND SETTING: Randomised, double-blind, parallel-group study conducted at 44 centres in Germany, Poland and the Czech Republic. PATIENTS: 643 patients (aged 19-86 years) with mainly mild-to-moderate essential hypertension received active double-blind treatment. INTERVENTIONS: Following a 2-week placebo run-in, eligible patients were randomly assigned to receive olmesartan medoxomil 20mg (n = 319) or candesartan cilexetil8mg (n = 324) once daily for 8 weeks. MAIN OUTCOME MEASURES: Changes from baseline in daytime, 24-hour and night-time diastolic (DBP) and systolic (SBP) blood pressures assessed by ambulatory blood pressure monitoring (ABPM), and changes from baseline in sitting cuff DBP and SBP. RESULTS: Mean decreases from baseline in daytime DBP by ABPM at weeks 1, 2 and 8 were 6.7, 8.4 and 9.3mm Hg, respectively, in the olmesartan medoxomil group compared with 5.3, 6.0 and 7.8mm Hg, respectively, in the candesartan cilexetil group. The between-group differences were significantly in favour of olmesartan medoxomil at all three timepoints (p </= 0.0126). Significant differences in favour of olmesartan medoxomil were also observed for mean 24-hour DBP and for mean daytime and 24-hour SBP by ABPM. Decreases from baseline in sitting cuff BP at trough were similar in the two groups (15-16mm Hg for DBP and 21mm Hg for SBP). Both treatments were well tolerated. CONCLUSIONS:Olmesartan medoxomil reduced daytime and 24-hour DBP and SBP, assessed by ABPM, more effectively than candesartan cilexetil at the doses tested. The majority of the treatment effect in both groups was seen after only 1 or 2 weeks of dosing, when the between-group differences were already statistically significant.
RCT Entities:
OBJECTIVE: To compare the antihypertensive efficacy of olmesartan medoxomil with that of candesartan cilexetil after 1, 2 and 8 weeks of treatment. DESIGN AND SETTING: Randomised, double-blind, parallel-group study conducted at 44 centres in Germany, Poland and the Czech Republic. PATIENTS: 643 patients (aged 19-86 years) with mainly mild-to-moderate essential hypertension received active double-blind treatment. INTERVENTIONS: Following a 2-week placebo run-in, eligible patients were randomly assigned to receive olmesartan medoxomil 20mg (n = 319) or candesartan cilexetil 8mg (n = 324) once daily for 8 weeks. MAIN OUTCOME MEASURES: Changes from baseline in daytime, 24-hour and night-time diastolic (DBP) and systolic (SBP) blood pressures assessed by ambulatory blood pressure monitoring (ABPM), and changes from baseline in sitting cuff DBP and SBP. RESULTS: Mean decreases from baseline in daytime DBP by ABPM at weeks 1, 2 and 8 were 6.7, 8.4 and 9.3mm Hg, respectively, in the olmesartan medoxomil group compared with 5.3, 6.0 and 7.8mm Hg, respectively, in the candesartan cilexetil group. The between-group differences were significantly in favour of olmesartan medoxomil at all three timepoints (p </= 0.0126). Significant differences in favour of olmesartan medoxomil were also observed for mean 24-hour DBP and for mean daytime and 24-hour SBP by ABPM. Decreases from baseline in sitting cuff BP at trough were similar in the two groups (15-16mm Hg for DBP and 21mm Hg for SBP). Both treatments were well tolerated. CONCLUSIONS:Olmesartan medoxomil reduced daytime and 24-hour DBP and SBP, assessed by ABPM, more effectively than candesartan cilexetil at the doses tested. The majority of the treatment effect in both groups was seen after only 1 or 2 weeks of dosing, when the between-group differences were already statistically significant.
Authors: J A Staessen; L Thijs; R Fagard; E T O'Brien; D Clement; P W de Leeuw; G Mancia; C Nachev; P Palatini; G Parati; J Tuomilehto; J Webster Journal: JAMA Date: 1999-08-11 Impact factor: 56.272
Authors: G Mancia; A Zanchetti; E Agabiti-Rosei; G Benemio; R De Cesaris; R Fogari; A Pessina; C Porcellati; A Rappelli; A Salvetti; B Trimarco; E Agebiti-Rosei; A Pessino Journal: Circulation Date: 1997-03-18 Impact factor: 29.690
Authors: Francesco Rozza; Valentina Trimarco; Raffaele Izzo; Mario Santoro; Maria Virginia Manzi; Marina Marino; Gianfranco Di Renzo; Bruno Trimarco Journal: High Blood Press Cardiovasc Prev Date: 2013-05-09